This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial


Mori, Koichiro, Inatomi, Satoshi, Ouchi, Kenzi, Azumi, Yoshihito, Tuchida, Takashi


Phytotherapy Research: PTR, Volume: 23, No.: 3, Pages.: 367-372

Year of Publication



A double-blind, parallel-group, placebo-controlled trial was performed on 50- to 80-year-old Japanese men and women diagnosed with mild cognitive impairment in order to examine the efficacy of oral administration of Yamabushitake (Hericium erinaceus), an edible mushroom, for improving cognitive impairment, using a cognitive function scale based on the Revised Hasegawa Dementia Scale (HDS-R). After 2 weeks of preliminary examination, 30 subjects were randomized into two 15-person groups, one of which was given Yamabushitake and the other given a placebo. The subjects of the Yamabushitake group took four 250 mg tablets containing 96% of Yamabushitake dry powder three times a day for 16 weeks. After termination of the intake, the subjects were observed for the next 4 weeks. At weeks 8, 12 and 16 of the trial, the Yamabushitake group showed significantly increased scores on the cognitive function scale compared with the placebo group. The Yamabushitake group’s scores increased with the duration of intake, but at week 4 after the termination of the 16 weeks intake, the scores decreased significantly. Laboratory tests showed no adverse effect of Yamabushitake. The results obtained in this study suggest that Yamabushitake is effective in improving mild cognitive impairment.; (c) 2008 John Wiley & Sons, Ltd.

Bibtex Citation

@article{Mori_2009, doi = {10.1002/ptr.2634}, url = {}, year = 2009, month = {mar}, publisher = {Wiley-Blackwell}, volume = {23}, number = {3}, pages = {367--372}, author = {Koichiro Mori and Satoshi Inatomi and Kenzi Ouchi and Yoshihito Azumi and Takashi Tuchida}, title = { Improving effects of the mushroom Yamabushitake ( Hericium erinaceus ) on mild cognitive impairment: a double-blind placebo-controlled clinical trial }, journal = {Phytother. Res.} }


agaricales, aged, aged, 80 and over, chemistry, cognition disorders, dietary supplements, double-blind method, drug therapy, female, humans, male, middle aged, mushroom, neuropsychological tests, nootropic agents, therapeutic use, yamabushitake

Countries of Study


Types of Dementia

Mild Cognitive Impairment (MCI)

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Herbal remedies, vitamins, dietary supplements